Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Construction in Progress (2016 - 2017)

Historic Construction in Progress for Northwest Biotherapeutics (NWBO) over the last 4 years, with Q4 2017 value amounting to $47.3 million.

  • Northwest Biotherapeutics' Construction in Progress rose 619.4% to $47.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was $47.3 million, marking a year-over-year increase of 619.4%. This contributed to the annual value of $47.3 million for FY2017, which is 619.4% up from last year.
  • According to the latest figures from Q4 2017, Northwest Biotherapeutics' Construction in Progress is $47.3 million, which was up 619.4% from $47.3 million recorded in Q3 2017.
  • Northwest Biotherapeutics' 5-year Construction in Progress high stood at $47.3 million for Q3 2017, and its period low was $44.6 million during Q4 2016.
  • For the 3-year period, Northwest Biotherapeutics' Construction in Progress averaged around $46.0 million, with its median value being $46.0 million (2015).
  • Its Construction in Progress has fluctuated over the past 5 years, first plummeted by 245.62% in 2016, then skyrocketed by 619.4% in 2017.
  • Quarter analysis of 3 years shows Northwest Biotherapeutics' Construction in Progress stood at $45.7 million in 2015, then dropped by 2.46% to $44.6 million in 2016, then rose by 6.19% to $47.3 million in 2017.
  • Its Construction in Progress was $47.3 million in Q4 2017, compared to $47.3 million in Q3 2017 and $46.2 million in Q2 2017.